BACKGROUND: Selection of the best treatment option for @entity1149 ( @entity1149 ) depends on optimal initial staging. OBJECTIVE: Evaluate the clinical impact of 18F-FDG PET/CT on the management of Thai @entity1 with @entity1149 . MATERIAL AND METHOD: Twenty-four @entity1 with @entity1149 underwent FDG PET/CTfor initial staging. The best treatment options between pre- and post-FDG PET/CT staging were identified for each @entity1 . Changes in treatment management decisions and the diagnostic values (sensitivity, specificity, positive predictive value, negative predictive value, and accuracy) of nodal and distant metastases were assessed. RESULTS: Pre-FDG PET/CT staging included five @entity1 with stage IA, four @entity1 with stage IB, one @entity1 with stage IIB, three @entity1 with stage IIIA, and 11 @entity1 with stage IV disease. A difference between pre- and post-FDG PET/CT staging was noted in 10/24 @entity1 (41.7%). FDG PET/CT examination resulted in upstaging in 7/24 @entity1 (29%) and downstaging in three @entity1 (12.5%). The pre-FDG PET/CT staging was accurate in 14/24 @entity1 (58.3%) while the post-FDG PET/CTstaging was accurate in 19/24 @entity1 (79.2%). The treatment management decisions were changed in 5/24 @entity1 (20.8%). FDG PET/CT prevented futile surgery in two @entity1 . CONCLUSION: FDG PET/CT has an important role in @entity1149 staging. Additional PET/CT information could influence therapeutic options and reduced unnecessary surgery in @entity1 with @entity3 .

18F-FDG PET/Contrast-Enhanced CT for Initial Staging and Strategic Treatment of XXXX : A Prospective Study.

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity1149 :: ('MESH:D002289', 'Disease') :: ['NSCLC', 'non-small cell lung cancer'] @entity3 :: ('MESH:D009362', 'Disease') :: ['metastatic disease']
@entity1149 :: (MESH:D002289,Disease) :: ['Non-Small Cell Lung Cancer']
